X

pharmaceuticals

Abbott’s (ABT) stock can give high returns, thanks to COVID-related tailwinds

The financial performance of Abbott Laboratories (NYSE: ABT) has been positively impacted by the high demand for COVID-related diagnostic services.…

Medtronic (MDT) goes the extra mile to emerge stronger from virus crisis

The pandemic has influenced the healthcare industry significantly, but not all the segments are impacted in the same way. While…

Solid pipeline makes ImmunoGen (IMGN) a good long-term investment

ImmunoGen Inc. (NASDAQ: IMGN) last week reported a profit after incurring losses in the first three quarters of last year.…

CVS Health Corp. (CVS) Earnings: 4Q20 Key Numbers

CVS Health Corporation (NYSE: CVS) reported fourth quarter 2020 earnings results today. Total revenues increased 4% to $69.5 billion compared…

Infographic: Highlights of Aurora Cannabis (ACB) Q2 2021 earnings report

Aurora Cannabis, Inc. (NYSE: ACB) on Thursday reported a loss for the second quarter of 2021, continuing the recent trend.…

Eylea recovery, COVID antibody cocktail make Regeneron an attractive bet

After last year's mixed performance, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) looks to take advantage of the robust pipeline and the…

Strong pipeline, M&A synergies to keep Bristol Myers on growth path

Bristol Myers Squibb Company (NYSE: BMY) is thriving on its multi-pronged growth plan, based on strategic acquisitions and the promising…

Bristol Myers (BMY) stock gains after Q4 results beat Street view

Bristol-Myers Squibb Company (NYSE: BMY) Thursday reported stronger-than-expected fourth-quarter results. The company's stock gained in the pre-market session soon after…

Infographic: Highlights of Merck & Co. (MRK)Q4 2020 earnings report

Merck & Co., Inc. (NYSE: MRK) reported weak earnings and sales for the fourth quarter of 2020. Worldwide sales edged…

AbbVie (ABBV) Earnings: 4Q20 Key Numbers

AbbVie Inc. (NYSE: ABBV) reported fourth quarter 2020 earnings results today. Worldwide net revenues rose 59.2% year-over-year to $13.8 billion…

Pfizer (PFE) Q4 Earnings: Key financials and quarterly highlights

Pfizer Inc. (NYSE: PFE) reported its fourth quarter 2020 earnings results today. Revenues increased 12% year-over-year to $11.7 billion. On…

Infographic: Vertex Pharmaceuticals (VRTX) 4Q20 Earnings Results

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported fourth quarter 2020 earnings results today. Total revenues increased 15% year-over-year to $1.62 billion.…

Where do these companies stand in the COVID-19 vaccine race?

After the struggle with the COVID-19 pandemic and its impacts clouding most of 2020, the rollout of vaccines against COVID-19…

Johnson & Johnson’s (JNJ) single-dose vaccine is effective but lags behind rivals

Johnson & Johnson (NYSE: JNJ) is the latest pharma company to provide results from the trial of its COVID-19 vaccine candidate.…

Fate Therapeutics (FATE) looks headed for a turnaround post-COVID

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharma company, has been drawing the market's attention after reporting positive results from…

Johnson & Johnson (JNJ): Strength in ecommerce drives growth in Consumer Health

Shares of Johnson & Johnson (NYSE: JNJ) gained nearly 3% in morning trade on Tuesday after the company reported fourth…

Johnson & Johnson (JNJ) beats market estimates in Q4

Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2020 financial results before the regular market hours on Tuesday. The pharmaceutical giant…

Merck (MRK) pulls out of the COVID-19 vaccine race; will focus on investigational therapeutic candidates

Merck & Co. Inc. (NYSE: MRK) has decided to discontinue the development of its COVID-19 vaccine candidates after its clinical…

COVID-related medical costs may weigh on UnitedHealth’s performance this year

The health insurance sector has been facing multiple challenges from the virus crisis, but market-leading healthcare firm UnitedHealth Group (NYSE:…

Latest study shows Eli Lilly’s (LLY) antibody reduces COVID-19 by 80%

Eli Lilly and Company (NYSE: LLY) announced that the results from its latest study indicated that its monoclonal antibody bamlanivimab…

Codexis (CDXS) may be moving closer to profitability, after beating slowdown

Biosciences company Codexis, Inc. (NASDAQ: CDXS) has emerged stronger from a rough patch, supported mainly by the resilience of its…